Evaxion Biotech A/S (EVAX)
EVAX Stock Price Chart
Explore Evaxion Biotech A/S interactive price chart. Choose custom timeframes to analyze EVAX price movements and trends.
EVAX Company Profile
Discover essential business fundamentals and corporate details for Evaxion Biotech A/S (EVAX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2021
Employees
46.00
Website
https://www.evaxion-biotech.comCEO
Christian Kanstrup
Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
EVAX Financial Timeline
Browse a chronological timeline of Evaxion Biotech A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 May 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.50.
Earnings released on 14 Aug 2025
EPS came in at -$0.76 falling short of the estimated -$0.50 by -52.00%, while revenue for the quarter reached $37.00K , missing expectations by -99.54%.
Earnings released on 27 May 2025
EPS came in at -$0.29 surpassing the estimated -$0.65 by +55.38%.
Earnings released on 26 Mar 2025
EPS came in at -$0.80 falling short of the estimated -$0.26 by -207.69%, while revenue for the quarter reached $122.00K , missing expectations by -92.65%.
Stock split effective on 14 Jan 2025
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Oct 2024
EPS came in at -$0.20 surpassing the estimated -$0.60 by +66.67%, while revenue for the quarter reached $3.03M , beating expectations by +82.38%.
Earnings released on 14 Aug 2024
EPS came in at -$0.60 falling short of the estimated $0.10 by -700.00%, while revenue for the quarter reached $153.89K , beating expectations by +28.24%.
Earnings released on 28 May 2024
EPS came in at $0.15 surpassing the estimated -$0.56 by +126.79%, while revenue for the quarter reached $50.88K , beating expectations by +27.20%.
Earnings released on 27 Mar 2024
EPS came in at -$0.80 surpassing the estimated -$1.60 by +50.00%, while revenue for the quarter reached $73.60K .
Stock split effective on 22 Jan 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 19 Dec 2023
EPS came in at -$10.50 falling short of the estimated -$0.19 by -5.43K%.
Earnings released on 18 Aug 2023
EPS came in at -$10.50 falling short of the estimated -$0.21 by -4.90K%.
Earnings released on 27 Apr 2023
EPS came in at -$14.50 falling short of the estimated -$0.24 by -5.94K%.
Earnings released on 28 Mar 2023
EPS came in at -$0.39 falling short of the estimated -$0.28 by -39.29%.
Earnings released on 14 Nov 2022
EPS came in at -$12.00 surpassing the estimated -$17.00 by +29.41%.
Earnings released on 10 Aug 2022
EPS came in at -$10.00 surpassing the estimated -$16.50 by +39.39%.
Earnings released on 11 May 2022
EPS came in at -$12.50 surpassing the estimated -$17.50 by +28.57%.
Earnings released on 22 Mar 2022
EPS came in at -$19.50 falling short of the estimated -$15.00 by -30.00%.
Earnings released on 9 Nov 2021
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%.
Earnings released on 12 Aug 2021
EPS came in at -$0.36 falling short of the estimated -$0.29 by -24.14%.
Earnings released on 13 May 2021
EPS came in at -$11.50 surpassing the estimated -$16.50 by +30.30%.
Earnings released on 6 Apr 2021
EPS came in at -$0.26 falling short of the estimated -$0.25 by -4.00%.
Earnings released on 5 Nov 2020
EPS came in at -$0.50 .
EVAX Stock Performance
Access detailed EVAX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.